The Fifth Nagoya International Blood and Marrow Transplantation Symposium

Unlimited possibilities of hematopoietic cell transplantation : lessons from the past and prospects for the future

April 19 (Sat), 20 (Sun) 2003 Nagoya JAPAN



Organized by Nagoya Blood and Marrow Transplantation Group Kyowa Hakko Kogyo Co., Ltd.

Welcome Message

On behalf of the Organizing Committee of the Fifth Nagoya International Blood and Marrow Transplantation Symposium I would like to welcome you to Nagoya.

Hematopoietic stem cell transplantation (HSCT), a frontrunner of regenerative medicine, has been widely used for treatment of leukemia, lymphoma, severe aplastic anemia and inborn metabolic disorders. Particularly, for those patients who have resistant disease or are at high risk to relapse, HSCT is the treatment of choice. In the past 10 years more than 14,000 transplants have been performed in Japan



by using stem cells from bone marrow, peripheral blood, or cord blood. Establishment of the Japan Bone Marrow Bank and the Japan Cord Blood Network has greatly promoted HSCT from unrelated donors; more than 4,500 bone marrow and more than 800 cord blood transplantations as of March 1, 2003.

We have recently seen some new developments in HSCT. The introduction of non-myeloablasive transplantation is likely to expand the indication of HSCT to elderly patients who are not possible to undergo conventional HSCT with high-dose chemo-radio-therapy. Clinical significance of histocompatibility antigen in HSCT has been further examined, and new concepts such as non-inherited maternal antigen (NIMA) complementary transplantation have been emerged. It has been also shown that bone marrow contains mesenchymal stem cells, which are capable to differentiate into various cells, including vascular endothelial cells and bone cells. These findings suggest that bone marrow and cord blood may be good sources for tissue engineering. Therefore, HSCT appears to have unlimited possibilities in the future.

This symposium has been organized jointly by Nagoya BMT group and Kyowa Hakko Kogyo Co. since 1996. The purpose of the meeting is to provide an international forum for exchanging the up-to-date information and experiences. We are happy that many leading physicians and investigators will participate in the program. I hope that valuable information of clinical relevance will be generated by all the participants during the meeting.

Hidehiko Saito, M.D.

Chairperson, Organizing Committee

Islehiko Saito

Symposium Committees

Hidehiko Saito Chairman National Nagoya Hospital

Vice Chairman Makoto Ogawa Aichi Cancer Center

> Yoshihisa Kodera The Japanese Red Cross Nagoya First Hospital

> > Nagova Daini Red Cross Hospital

Yasuo Morishima Aichi Cancer Center

Secretariat General Hiroshi Sao Meitetsu Hospital

> Yoshihisa Morishita JA Aichi Showa Hospital

Organizing Committee Yoshiki Akatsuka Aichi Cancer Center Nobuhiko Emi

Seiichi Goto

Nagoya University

Motohiro Hamaguchi National Nagoya Hospital

Noriyuki Hirabayashi Nagoya Daini Red Cross Hospital

Keizo Horibe National Nagova Hospital Takuji Ichihashi Okazaki City Hospital Atsushi Ichikawa Tajimi Prefectural Hospital

Hiroatsu lida Meitetsu Hospital

Tadashi Kamiya Aichi Red Cross Blood Center

The Japanese Red Cross Nagoya First Hospital Koji Kato

Tomohiro Kinoshita Nagoya University Kunio Kitamura Ichinomiya City Hospital

Kenjiro Kitaori The Japanese Red Cross Nagoya First Hospital

JA Aichi Showa Hospital Akio Kohno

Seiji Kojima Nagoya University

Hiroshi Kosugi Ogaki Municipal Hospital Fumio Maruyama Fujita Health University

The Japanese Red Cross Nagoya First Hospital Takaharu Matsuyama

Shuichi Mizuta Anjo Kosei Hospital Komaki City Hospital Kazuyuki Naito Nagoya University Tomoki Naoe Michinori Ogura Aichi Cancer Center Ekisaikai Hospital Takayoshi Shimokawa Isamu Sugiura Toyohashi City Hospital Aichi Cancer Center Hirofumi Taji Aichi Medical University Shigeru Takamoto

Aichi-Medical University Kazuya Tsuboi Keitaro Tsushita Chukyo Hospital Kazuhito Yamamoto Nagoya University

Kunio Yano Hamamatsu Medical Center Makoto Yazaki Moriyama Medical Hospital

Atsushi Wakita Nagoya City University

Central Convention Service, Inc. Symposium Office

1-45 Shirakabe, Higashi-ku, Nagoya 461-0011, Japan

Phone: 052-971-5550 / FAX: 052-951-3600

List of Speakers

John A. Hansen Member, Fred Hutchinson Cancer Research Center

Professor of Medicine, University of Washington

U.S.A.

Norbert Schmitz Abteilung Hämatologie

Allgemenes Krankenhaus St. Georg

Germany

Takayuki Asahara Kobe Institute of Biomedical Research Innovative

Japan

Yoshiki Akatsuka Division of Immunology

Aichi Cancer Center Research Institute

Japan

Katharine C. Hsu Memorial Sloan-Kettering Cancer Center

Immunogenetics Laboratory

U.S.A.

Andrea Velardi Professor and Chair of Clinical Immunology

Division of Hematology and Clinical Immunology

Perugia University School of Medicine

Italy

Tatsuo Ichinohe Department of Hematology / Oncology

Graduate School of Medicine, Kyoto University

Japan

General Information

Date:

Saturday, 19 to Sunday, 20 April, 2003

Venue:

The first day - Day time - Telepia-Hall

1-14-27, Higashisakura, Higashi-ku, Nagoya

- Night time - Nagoya Tokyu Hotel

4-6-8, Sakae, Naka-ku, Nagoya

The second day

Telepia-Hall

1-14-27, Higashisakura, Higashi-ku, Nagoya

Registration:

Registration Desk opens

Saturday, 19 April 13:00 - 17:30 Telepia-Hall

18:00 – 20:30 Nagoya Tokyu Hotel

Sunday, 20 April 9:05

9:05 - 12:50 Telepia-Hall

Main Topics:

"Unlimited possibilities of hematopoietic cell transplantation:

lessons from the past and prospects for the future"

Symposium:

Saturday, 19 April 13:45 - 17:45 Telepia-Hall

20:30 - 21:30 Nagoya Tokyu Hotel

Sunday, 20 April 9:15 - 13:05 Telepia-Hall

Social Meeting:

Saturday, 19 April 18:30 - 20:30 Nagoya Tokyu Hotel

Official Language: English

Scientific Program

- Saturday, April 19 -

Symposium site

13:45 Opening remarks:

Hidehiko Saito

(Nagoya National Hospital, Japan)

14:00 Keynote Address:

"Overview on the allogeneic intervention for hematological malignancies"

Chairperson: Yoshihisa Kodera (Japanese Red Cross Nagoya First

Hospital, Japan)

14:05-14:50 "CML and acute leukemias"

John A. Hansen (Fred Hutchinson Cancer Research

Center, U.S.A.)

14:55–15:40 "Current treatment of lymphoma"

Norberts Schmitz (Allgemenes Krankenhaus St. Georg,

Germany)

Intermission for 15 min.

16:00-17:45 **Session 1 Table discussion:**

"The role and indication of allogeneic transplantations such as BMT,

PBSCT, UCB, RCT for hematological malignancies"

Chairpersons: Hikaru Nakajima (University of Minnesota, U.S.A.)

Shinichiro Okamoto (Keio University, Japan)

Panelists: J.A. Hansen, N. Schmitz, A Velardi, K.C. Hsu

Move to Tokyu Hotel

20:30-21:30 Night session:

Chairperson: Toyoaki Murohara (Nagoya University, Japan)

"Plasticity of mesenchimal stem cells derived from bone marrow."

Takayuki Asahara (Kobe Institute of Biomedical

Research Innovative, Japan)

- Sunday, April 20 -

Symposium site

| 9:15 | Session 2 : Clinical significance of histocompatibility for allogeneic-HSCT. | | |
|-------------|---|---------------------|---|
| | Chairperson: | Yasuo Morishima | (Aichi Cancer Center, Japan) |
| 9:20-10:00 | "Progress of histocompatibility research and its application to HSCT | | |
| | from the 13th International Histocompatibility Workshop and Congress." | | |
| | | John A. Hansen | (Fred Hutchinson Cancer Research |
| | | | Center, U.S.A.) |
| 10:00-10:30 | "Role of HLA class I and minor HA for unrelated BMT through JMDP." | | |
| | | Yoshiki Akatsuka | (Aichi Cancer Center, Japan) |
| 10:30-11:10 | "Characterization of natural killer cell Ig-like receptor (KIRs) and their | | |
| | effects to HSC | T." | |
| | | Katherine C. Hsu | (Memorial Sloan-Kettering Cancer |
| | | | Center, U.S.A.) |
| 11:10–11:30 | Discussion | | |
| 11:30–12:10 | "Impact of donor natural killer cell alloreactivity on allogeneic hematopoietic | | |
| | transplantation | 33 | · |
| | | Andrea Velardi | (Perugia University School of Medicine, |
| | | | Italy) |
| 12:10-12:30 | "Non-inherited maternal antigen (NIMA) complementary transplantation." | | |
| | | Tatsuo Ichinohe | (Kyoto University, Japan) |
| 12:30-12:50 | Discussion | | |
| | | | |
| 12:50-13:05 | Closing remarks : | | |
| | | Yoshihisa Morishita | (JA Aichi Showa Hospital, Japan) |

Other Information

Symposium site

Telepia-Hall 1-14-27, Higashisakura, Higashi-ku, Nagoya

461-8501 Japan

Tel: +81-52-954-1165

Hotel accommodation

Nagoya Tokyu Hotel 4-6-8,Sakae, Naka-ku, Nagoya 460-0008 Japan

Tel: +81-52-251-2411